Tanabe Mitsubishi Starts Global Phase III Trials With Alzheimer’s Drug
This article was originally published in PharmAsia News
Executive Summary
Tanabe Mitsubishi has begun global Phase III trials for Alzheimer’s disease drug MT-4666 (encenicline) for which they have rights in Japan and other Asian countries.
Tanabe Mitsubishi has begun global Phase III trials with Alzheimer’s disease drug MT-4666 (encenicline) for which they have the rights in Japan and other Asian countries, the company recently announced. Completion of primary endpoint data collection is planned for January 2017. MT-4666 is an orally administered drug with α7 nicotinic acetylcholine receptor agonist action, and is expected to cause less side effects than current drugs. The novel drug was originally made by EnVivo, but Tanabe Mitsubishi acquired exclusive development and sales rights for Japan and Asia in 2009. EnVivo will handle international trials, while Tanabe Mitsubishi is responsible for Japan trials. (Click Here For More – Japanese Language
)
“Tanabe Mitsubishi Starts International P3 Trials With New Alzheimer Drug, Plans Completion For 2017” - mixonline.jp 2/6/2014